The reacquisition of bota-vec represents a high-upside opportunity for MGTX given the strong secondary data, regulatory designations, and existing manufacturing readiness. Traders should monitor upcoming BLA/MAA submissions and potential FDA feedback. Despite the primary endpoint miss, the robust secondary outcomes and unmet need may support approval. The $25M upfront is manageable for a $916M market cap company, and future royalties preserve optionality.
Price Chart
Executive Summary
MeiraGTx has reacquired global rights to botaretigene sparoparvovec (bota-vec) for XLRP from Johnson & Johnson for a $25M upfront payment and future milestones, with plans to file for regulatory approval in the U.S., EU, and Japan. The Phase 3 LUMEOS trial showed strong secondary endpoint improvements in vision despite missing the primary endpoint, and the company intends to launch in 2027 if approved.
Key Financial Metrics
Key Facts
- MeiraGTx reacquired bota-vec from Johnson & Johnson under an asset purchase agreement.
- Upfront payment is $25 million in cash; additional one-time regulatory/commercial milestone and high double-digit royalty on global net sales starting mid-2029.
- Plans to file BLA and MAA in U.S., EU, and Japan immediately; potential launch in 2027.
- Phase 3 LUMEOS study missed primary endpoint (VMA) but showed statistically significant and clinically meaningful improvements across multiple secondary endpoints in all three domains of vision.
- 40% of treated patients showed improvement in ≥2 endpoints across different vision domains vs. 0% in control.
- MeiraGTx is the commercial manufacturer, has completed PPQ, and holds MHRA and Irish QC facility licenses; hundreds of vials already manufactured.
- FDA Fast Track and Orphan Drug, EU PRIME and ATMP designations granted.
Financial Impact
$25 million upfront cash payment, future milestone tied to U.S. approval and sales performance, and high double-digit royalty on global net sales
Risk Factors
- Regulatory risk: The primary endpoint was not met, which could delay or complicate approval despite strong secondary data.
- Commercial execution risk: MeiraGTx must transition from clinical to commercial stage with limited prior experience.
- Dilution risk: Future capital raises may be needed to fund near-term commercialization efforts.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3275204 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 144 | $10.82 | awaiting T+60 | — | $9.18 (−15.16%) |
Sep 24, 2026 4w ago | 3 | $10.91 | awaiting T+60 | — | $9.18 (−15.86%) |
Sep 23, 2026 4w ago | 8-K | $11.75 | awaiting T+60 | — | $9.18 (−21.87%) |
Aug 18, 2026 9w ago | 144 | $14.97 | awaiting T+60 | — | $9.18 (−38.68%) |
Aug 13, 2026 10w ago | 8-K | $12.67 | awaiting T+60 | — | $9.18 (−27.55%) |
Aug 13, 2026 10w ago | Press Release | $12.67 | awaiting T+60 | — | $9.18 (−27.55%) |
Jul 7, 2026 16w ago | 8-K | $14.66 $11.00 | ▼ −24.97% | ▼ −26.96% | $9.18 (−37.38%) |
May 19, 2026 22w ago | 144 | $9.58 $13.52 | ▲ +41.13% | ▲ +36.12% | $9.18 (−4.18%) |
May 14, 2026 23w ago | 8-K | $9.95 $13.02 | ▲ +30.85% | ▲ +27.27% | $9.18 (−7.74%) |
May 14, 2026 23w ago | Press Release | $9.95 $13.02 | ▲ +30.85% | ▲ +27.27% | $9.18 (−7.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers